TAC-D Plus Tablet is a powerful combination therapy designed to manage polymicrobial infections involving fungal, protozoal, and bacterial organisms. This combination typically includes Fluconazole, a triazole antifungal; Tinidazole, a nitroimidazole antiprotozoal and antibacterial agent; and Ofloxacin, a fluoroquinolone antibiotic. Together, these agents act synergistically to eradicate mixed infections that may occur in the gastrointestinal, urogenital, or vaginal tract.

Fluconazole in the TAC-D Plus Tablet interferes with the synthesis of ergosterol, an essential component of fungal cell membranes, ultimately causing cell death. Tinidazole acts by disrupting DNA structure and inhibiting nucleic acid synthesis in protozoa and anaerobic bacteria, making it effective against organisms such as Entamoeba histolytica, Giardia lamblia, and Trichomonas vaginalis. Ofloxacin inhibits bacterial DNA gyrase, an enzyme critical for DNA replication and repair, thereby halting bacterial growth.

TAC-D Plus Tablet is particularly effective in conditions where simultaneous fungal and bacterial or protozoal infections coexist, such as vaginal discharge syndromes, pelvic inflammatory disease, mixed intestinal infections, and sexually transmitted infections. It is often used in gynecology, urology, and gastrointestinal medicine to deliver broad antimicrobial coverage with a single convenient tablet.

This combination medication is manufactured by Bluepill Express under stringent quality controls, conforming to WHO-GMP and ISO standards. It is developed using high-grade raw materials and is subjected to rigorous in-process testing to ensure consistency, stability, and safety. The finished product undergoes strict post-production quality checks and is packaged in protective blisters to maintain its potency and shelf life.

TAC-D Plus Tablet offers a convenient once-daily dosing regimen, making it patient-friendly and improving compliance in acute or chronic infections. Its broad-spectrum nature reduces the need for multiple prescriptions, streamlining therapy and minimizing the risk of incomplete treatment. This product is especially valuable in primary care and specialty practices, where empirical treatment of mixed infections is often required before culture results are available.

Bluepill Express offers full-service third-party manufacturing for TAC-D Plus Tablet, including custom branding, design, and international regulatory support. The company provides comprehensive documentation such as the Certificate of Analysis, Stability Data, CTD Dossiers, and product literature, making it suitable for both domestic markets and international distribution.